<DOC>
	<DOCNO>NCT02397538</DOCNO>
	<brief_summary>An Open-label , Fixed-sequence , Crossover Study Evaluate Pharmacokinetic Interaction Safety multiple oral dos Fimasartan/Amlodipine Rosuvastatin Healthy Male Subjects .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetic Interaction Safety After Multiple Oral Doses Fimasartan/Amlodipine Rosuvastatin Healthy Male Subjects</brief_title>
	<detailed_description>After subject sign informed consent voluntarily , go screening period within 28 day . As period I , subject Cohort1 take fimasartan Amlodipine 10 day subject Cohort2 take rosuvastatin 6 day . And , period II , subject Cohorts take fimasartan , Amlodipine rosuvastatin Cohort1 case 6 day Cohort2 case 10 10days . For Fimasartan , subject Cohort1 blood sample 8th , 9th , 14th , 15th day medication , 10th 16th day 0.25 , 0.5 , 0.75 , 1 , 1.5 , 2 , 3 , 4 , 5 , 6 , 8 , 12 24hour medication ( 32 time total ) . For Amlodipine , subject Cohort1 blood sample 8th , 9th , 14th , 15th day medication , 10th 16th day 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 24hour medication ( 30 time total ) . For Rosuvastatin N-desmethyl rosuvastatin , subject Cohort2 blood sample 4th , 5th , 14th , 15th day medication , 6th 16th day 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 10 , 12 24hour medication ( 28 time total ) .</detailed_description>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Healthy male subject , age 19 50 year screen . 2 . Body weight within ± 20 % ideal body weight ( IBW ) ( kg ) = { height ( cm ) 100 } * 0.9 1 . History illness may affect absorption , distribution , metabolism excretion ( hepatobiliary , renal , cardiovascular , endocrine ( e.g. , hypothyroidism ) , respiratory , gastrointestinal , hematooncology , central nervous system , psychiatric musculoskeletal system ) 2 . Hypotension ( systolic ≤ 100 mmHg diastolic ≤ 65 mmHg ) hypertension ( systolic ≥ 140 mmHg diastolic ≥ 90 mmHg ) , measure screen 3 . Active liver disease , level ALT ( Aspartate Transaminase ) , AST ( Alanin Transaminase ) total bilirubin &gt; 1.25 x upper limit normal 4 . History gastrointestinal disease ( i.g. , Crohn 's disease , active peptic ulcer ) resection operation may affect absorption study drug ( exclude simple appendectomy herniorrhaphy ) ] 5 . Participation study within 3 month prior first administration study drug ( The finish time previous study day last administration study drug )</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Fimasartan</keyword>
</DOC>